目次

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION
2.1. DEFINITION
2.2. SCOPE OF THE STUDY
2.2.1. RESEARCH OBJECTIVE
2.2.2. ASSUMPTIONS
2.2.3. LIMITATIONS

3. RESEARCH METHODOLOGY
3.1. OVERVIEW
3.2. DATA MINING
3.3. SECONDARY RESEARCH
3.4. PRIMARY RESEARCH
3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2. BREAKDOWN OF PRIMARY RESPONDENTS
3.5. FORECASTING MODALITY
3.6. MARKET SIZE ESTIMATION
3.6.1. BOTTOM-UP APPROACH
3.6.2. TOP-DOWN APPROACH
3.7. DATA TRIANGULATION
3.8. VALIDATION

4. MARKET DYNAMICS
4.1. OVERVIEW
4.2. DRIVERS
4.3. RESTRAINTS
4.4. OPPORTUNITIES

5. MARKET FACTOR ANALYSIS
5.1. VALUE CHAIN ANALYSIS
5.2. PORTER’S FIVE FORCES ANALYSIS
5.2.1. BARGAINING POWER OF SUPPLIERS
5.2.2. BARGAINING POWER OF BUYERS
5.2.3. THREAT OF NEW ENTRANTS
5.2.4. THREAT OF SUBSTITUTES
5.2.5. INTENSITY OF RIVALRY
5.3. COVID-19 IMPACT ANALYSIS
5.3.1. IMPACT ON SUPPLY CHAIN
5.3.2. IMPACT ON PRICING
5.3.3. IMPACT ON REGIONS
5.3.4. IMPACT ON PRODUCTION
5.3.5. IMPACT ON DEMAND-SUPPLY GAP

6. GLOBAL PERIPHERAL NERVE STIMULATOR MARKET, BY PRODUCT
6.1. OVERVIEW
6.2. TRANSCUTANEOUS
6.3. PERCUTANEOUS
6.4. IMPLANTABLE

7. GLOBAL PERIPHERAL NERVE STIMULATOR MARKET, BY DEVICE TYPE
7.1. OVERVIEW
7.2. STIMULATORS
7.3. CPNB CATHETERS
7.4. PAIN PUMPS
7.5. OTHERS

8. GLOBAL PERIPHERAL NERVE STIMULATOR MARKET, BY STIMULATING FEATURE
8.1. OVERVIEW
8.2. STIMULATOR MACHINES WITH TRAIN OF FOUR (TOF) MONITORING FEATURES
8.3. MACHINES WITHOUT TOF FEATURES

9. GLOBAL PERIPHERAL NERVE STIMULATOR MARKET, BY END USER
9.1. OVERVIEW
9.2. HOSPITAL & CLINICS
9.3. AMBULATORY SURGERY CENTERS
9.4. OTHERS

10. GLOBAL PERIPHERAL NERVE STIMULATOR MARKET, BY REGION
10.1. OVERVIEW
10.1. NORTH AMERICA
10.1.1. US
10.1.2. CANADA
10.2. EUROPE
10.2.1. GERMANY
10.2.2. FRANCE
10.2.3. UK
10.2.4. ITALY
10.2.5. SPAIN
10.2.6. REST OF EUROPE
10.3. ASIA-PACIFIC
10.3.1. CHINA
10.3.2. INDIA
10.3.3. JAPAN
10.3.4. SOUTH KOREA
10.3.5. AUSTRALIA
10.3.6. REST OF ASIA-PACIFIC
10.4. REST OF THE WORLD
10.4.1. MIDDLE EAST
10.4.2. AFRICA
10.4.3. LATIN AMERICA

11. COMPETITIVE LANDSCAPE
11.1. OVERVIEW
11.2. COMPETITIVE ANALYSIS
11.3. MARKET SHARE ANALYSIS
11.4. MAJOR GROWTH STRATEGY IN THE GLOBAL PERIPHERAL NERVE STIMULATOR MARKET,
11.5. COMPETITIVE BENCHMARKING
11.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL PERIPHERAL NERVE STIMULATOR MARKET,
11.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES
11.7.1. NEW PRODUCT LAUNCH/SERVICE DEPLOYMENT
11.7.2. MERGER & ACQUISITIONS
11.7.3. JOINT VENTURES
11.8. MAJOR PLAYERS FINANCIAL MATRIX
11.8.1. SALES & OPERATING INCOME, 2022
11.8.2. MAJOR PLAYERS R&D EXPENDITURE. 2022

12. COMPANY PROFILES
12.1. MEDTRONIC
12.1.1. COMPANY OVERVIEW
12.1.2. FINANCIAL OVERVIEW
12.1.3. PRODUCTS OFFERED
12.1.4. KEY DEVELOPMENTS
12.1.5. SWOT ANALYSIS
12.1.6. KEY STRATEGIES
12.2. B. BRAUN SE
12.2.1. COMPANY OVERVIEW
12.2.2. FINANCIAL OVERVIEW
12.2.3. PRODUCTS OFFERED
12.2.4. KEY DEVELOPMENTS
12.2.5. SWOT ANALYSIS
12.2.6. KEY STRATEGIES
12.3. BOSTON SCIENTIFIC CORPORATION
12.3.1. COMPANY OVERVIEW
12.3.2. FINANCIAL OVERVIEW
12.3.3. PRODUCTS OFFERED
12.3.4. KEY DEVELOPMENTS
12.3.5. SWOT ANALYSIS
12.3.6. KEY STRATEGIES
12.4. CURONIX LLC
12.4.1. COMPANY OVERVIEW
12.4.2. FINANCIAL OVERVIEW
12.4.3. PRODUCTS OFFERED
12.4.4. KEY DEVELOPMENTS
12.4.5. SWOT ANALYSIS
12.4.6. KEY STRATEGIES
12.5. SPR THERAPEUTICS
12.5.1. COMPANY OVERVIEW
12.5.2. FINANCIAL OVERVIEW
12.5.3. PRODUCTS OFFERED
12.5.4. KEY DEVELOPMENTS
12.5.5. SWOT ANALYSIS
12.5.6. KEY STRATEGIES
12.6. AVNS
12.6.1. COMPANY OVERVIEW
12.6.2. FINANCIAL OVERVIEW
12.6.3. PRODUCTS OFFERED
12.6.4. KEY DEVELOPMENTS
12.6.5. SWOT ANALYSIS
12.6.6. KEY STRATEGIES
12.7. TELEFLEX INCORPORATED
12.7.1. COMPANY OVERVIEW
12.7.2. FINANCIAL OVERVIEW
12.7.3. PRODUCTS OFFERED
12.7.4. KEY DEVELOPMENTS
12.7.5. SWOT ANALYSIS
12.7.6. KEY STRATEGIES
12.8. SUNMED
12.8.1. COMPANY OVERVIEW
12.8.2. FINANCIAL OVERVIEW
12.8.3. PRODUCTS OFFERED
12.8.4. KEY DEVELOPMENTS
12.8.5. SWOT ANALYSIS
12.8.6. KEY STRATEGIES
12.9. XAVANT TECHNOLOGY (PTY) LTD
12.9.1. COMPANY OVERVIEW
12.9.2. FINANCIAL OVERVIEW
12.9.3. PRODUCTS OFFERED
12.9.4. KEY DEVELOPMENTS
12.9.5. SWOT ANALYSIS
12.9.6. KEY STRATEGIES
12.10. VYGON
12.10.1. COMPANY OVERVIEW
12.10.2. FINANCIAL OVERVIEW
12.10.3. PRODUCTS OFFERED
12.10.4. KEY DEVELOPMENTS
12.10.5. SWOT ANALYSIS
12.10.6. KEY STRATEGIES

13. APPENDIX
13.1. REFERENCES
13.2. RELATED REPORTS